RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
1. A composition comprising:
I) a double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of a target gene via RNA interference, having a sense strand and an antisense strand and comprising formula (A):
wherein, the upper strand is the sense strand and the lower strand is the antisense strand of the double-stranded nucleic acid molecule; wherein the antisense strand comprises a sequence having at least 15 nucleotides that are complementary to a target RNA sequence encoded by the target gene and the sense strand comprises a sequence that is complementarity to the antisense strand; each N is independently a nucleotide which is unmodified or chemically modified or is optionally a non-nucleotide; each B is independently a terminal cap that is present or absent; (N) represents overhanging nucleotides, each of which is independently unmodified or chemically modified; [N] represents nucleotides at the 5′-terminus of the antisense strand; X1 and X2 are independently integers from 0 to 4; X3 is an integer from 15 to 30; X4 is an integer from 12 to 27; and X5 is an integer from 1-6, provided that the sum of X4 and X5 is an integer from 15-30; and wherein
(a) five or more pyrimidine nucleotides in NX4 positions are 2′-O-alkyl nucleotides;
(b) five or more purine nucleotides in NX4 positions are 2′-halo nucleotides;
(c) five or more pyrimidine nucleotides in NX3 positions are 2′-O-alkyl nucleotides;
(d) five or more purine nucleotides in Nx3 positions are 2′-halo nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides; and
II) a cationic lipid comprising 13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13 16-dien-1-amine.
2. The composition according to claim 1 , wherein:
(a) five or more pyrimidine nucleotides in NX4 positions are 2′-O-methyl nucleotides;
(b) five or more purine nucleotides in NX4 positions are 2′-deoxy-2′-fluoro nucleotides;
(c) five or more pyrimidine nucleotides in NX3positions are 2′-O-methyl nucleotides;
(d) five or more purine nucleotides in NX3 positions are 2′-deoxy-2′-fluoro nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides.
3. The composition according to claim 1 , wherein:
(a) 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides in NX4 positions are 2′-O-methyl nucleotides;
(b) 5, 6, 7, 8, 9, 10 or more purine nucleotides in NX4 positions are 2′-deoxy-2′-fluoro nucleotides;
(c) 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides in NX3 positions are 2′-O-methyl nucleotides;
(d) 5, 6, 7, 8, 9, 10 or more purine nucleotides in NX3 positions are 2′-deoxy-2′-fluoro nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides.
4. The composition according to claim 1 , wherein X5 is 3.
5. The composition according to claim 4 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. each N1, N2, and N3 is a ribonucleotide; or
b. each N1, N2, and N3 is a 2′-deoxy-2′-fluoro nucleotide; or
c. each N1, N2, and N3 is a 2′-deoxy nucleotide; or
d. each N1, N2, and N3 is a 2′-O-alkyl nucleotide; and
e. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
6. The composition according to claim 4 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxynucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
7. The composition according to claim 4 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-O-methyl nucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
8. The composition according to claim 4 , wherein the three [N] nucleotides of formula A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy nucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
9. The composition according to claim 4 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy-2′-fluoro nucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
10. The composition according to claim 1 , wherein X1 is 2 and X2 is 2.
11. The composition according to claim 1 , wherein X5 is 3, X1 is 2 and X2 is 2.
12. The composition according to claim 1 , wherein said double-stranded short interfering nucleic acid (siNA) molecule includes one or more universal base substitutions.
13. The composition according to claim 1 , wherein said double-stranded short interfering nucleic acid (siNA) molecule includes one or more LNA substitutions.
14. The composition according to claim 1 , wherein the nucleotide at position 14 from the 5′-end of the antisense strand of said double-stranded short interfering nucleic acid (siNA) molecule is a 2′-deoxy-2′-fluoro nucleotide.
15. The composition according to claim 1 , wherein one or more overhang nucleotides of said double-stranded short interfering nucleic acid (siNA) molecule is a 2′-O-methyl nucleotide.
16. The composition according to claim 1 , wherein said double-stranded short interfering nucleic acid (siNA) molecule includes at least one phosphorothioate internucleotide linkage.
17. The composition according to claim 1 , wherein X5=3; each X1 and X2=1 or 2; X3=18, 19, 20, 21, 22, or 24, and X4=17, 18, 19, 20, 21, 22, or 23.
18. The composition according to claim 1 , wherein X5=3; each X1 and X2=2; X3=19, and X4=16.
19. A double-stranded short interfering nucleic acid (s NA) molecule that inhibits the expression of a target gene via RNA interference, having a sense strand and an antisense strand and comprising formula (A):
wherein, the upper strand is the sense strand and the lower strand is the antisense strand of the double-stranded nucleic acid molecule; wherein the antisense strand comprises a sequence having at least 15 nucleotides that are complementary to a target RNA sequence encoded by the target gene and the sense strand comprises a sequence that is complementarity to the antisense strand; each N is independently a nucleotide which is unmodified or chemically modified or is optionally a non-nucleotide; each B is independently a terminal cap that is present or absent; (N) represents overhanging nucleotides, each of which is independently unmodified or chemically modified; [N] represents nucleotides at the 5′-terminus of the antisense strand; X1 and X2 are independently integers from 0 to 4; X3 is an integer from 15 to 30; X4 is an integer from 12 to 27; and X5 is an integer from 1-6, provided that the sum of X4 and X5 is an integer from 15-30; and wherein
(a) all pyrimidine nucleotides in NX4 positions are 2′-O-alkyl nucleotides;
(b) all purine nucleotides in NX4 positions are 2′-halo nucleotides;
(c) all pyrimidine nucleotides in NX3 positions are 2′-O-alkyl nucleotides;
(d) all purine nucleotides in NX3 positions are 2′-halo nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides;
(f) the nucleotide at position 14 from the 5′-end of the antisense strand is a 2′-deoxy-2′-fluoro nucleotide regardless of whether it is a purine or pyrimidine; and
(g) [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein
i) N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy nucleotide; or
ii) N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy-2′-fluoro nucleotide; or
iii) N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxynucleotide; or
iv) N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-O-methyl nucleotide; or
v) N1, N2, and N3 are all ribonucleotides having phosphorothioate internucleotide linkages.
20. A polymer comprising the double-stranded short interfering nucleic acid (siNA) molecule according to claim 19 .
21. A compound comprising the double-stranded short interfering nucleic acid (siNA) molecule according to claim 19 covalently attached to a ligand.
22. A lipid nanoparticle composition comprising the double-stranded short interfering nucleic acid (siNA) molecule according to claim 19 .
23. The lipid nanoparticle composition according to claim 22 , further comprising:
(a) (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;
(b) cholesterol;
(c) DSPC; and
(d) PEG-DMG.
24. The lipid nanoparticle composition according to claim 23 , wherein the (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, cholesterol, DSPC, and PEG-DMG have a molar ratio of 50:30:10:2 respectively.
25. A composition comprising the double-stranded short interfering nucleic acid (siNA) molecule according to claim 19 and a pharmaceutically acceptable carrier or diluent.